Functional and genetic analysis in type 2 diabetes of Liver X receptor alleles – a cohort study

Ingrid Dahlman1, Maria Nilsson2, Harvest F Gu3, Cecile Lecoeur4, Suad Efendic3, Claes G Östenson3, Kerstin Brismar3, Jan-Åke Gustafsson2,6, Philippe Froguel4,5, Martine Vaxillaire4, Karin Dahlman-Wright2 and Knut R Steffensen*2

Address: 1Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden, 2Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden, 3Rolf Luft Center for Diabetes Research, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden, 4CNRS UMR 8090 Institute of Biology, Pasteur Institute of Lille and Lille 2 Droit et Santé University, Lille, France, 5Genomic Medicine, Hammersmith Hospital, Imperial College, London, UK and 6Center for Nuclear Receptors and Cell Signaling, Department of Cell Biology and Biochemistry, University of Houston, Texas 77 204, USA

Email: Ingrid Dahlman - ingrid.dahlman@ki.se; Maria Nilsson - nilsson_anna_maria@yahoo.se; Harvest Gu - harvest.gu@molmed.ki.se; Cecile Lecoeur - cecile.lecoeur@good.ibl.fr; Suad Efendic - Suad.Efendic@molmed.ki.se; Claes G Östenson - claes.ostensson@karolinska.se; Kerstin Brismar - kerstin.brismar@ki.se; Jan-Åke Gustafsson - jan-ake.gustafsson@mednut.ki.se; Philippe Froguel - philippe.froguel@good.ibl.fr; Martine Vaxillaire - martine.vaxillaire@good.ibl.fr; Karin Dahlman-Wright - Karin.Dahlman-Wright@ki.se; Knut R Steffensen* - knut.steffensen@ki.se

* Corresponding author

Abstract

Background: Liver X receptor alpha (LXRA) and beta (LXRB) regulate glucose and lipid homeostasis in model systems but their importance in human physiology is poorly understood. This project aimed to determine whether common genetic variations in LXRA and LXRB associate with type 2 diabetes (T2D) and quantitative measures of glucose homeostasis, and, if so, reveal the underlying mechanisms.

Methods: Eight common single nucleotide polymorphisms in LXRA and LXRB were analyzed for association with T2D in one French cohort (N = 988 cases and 941 controls), and for association with quantitative measures reflecting glucose homeostasis in two non-diabetic population-based samples comprising N = 697 and N = 1344 adults. Investigated quantitative phenotypes included fasting plasma glucose, serum insulin, and HOMAIR as measure of overall insulin resistance. An oral glucose tolerance test was performed in N = 1344 of adults. The two alleles of the proximal LXRB promoter, differing only at the SNP rs17373080, were cloned into reporter vectors and transiently transfected, whereupon allele-specific luciferase activity was measured. rs17373080 overlapped, according to in silico analysis, with a binding site for Nuclear factor 1 (NF1). Promoter alleles were tested for interaction with NF1 using direct DNA binding and transactivation assays.

Results: Genotypes at two LXRB promoter SNPs, rs35463555 and rs17373080, associated nominally with T2D (P values 0.047 and 0.026). No LXRA or LXRB SNP associated with quantitative measures reflecting glucose homeostasis. The rs17373080 C allele displayed higher basal transcription activity (P value < 0.05). The DNA-mobility shift assay indicated that oligonucleotides corresponding to either rs17373080 allele bound NF1 transcription factors in whole cell extracts.
to the same extent. Different NFI family members showed different capacity to transactivate the LXRB gene promoter, but there was no difference between promoter alleles in NFI induced transactivation activity.

Conclusion: Variations in the LXRB gene promoter may be part of the aetiology of T2D. However, the association between LXRB rs35463555 and rs17373080, and T2D are preliminary and needs to be investigated in additional larger cohorts. Common genetic variation in LXRA is unlikely to affect the risk of developing T2D or quantitative phenotypes related to glucose homeostasis.

Background
Type 2 diabetes (T2D) is a common cause of morbidity and mortality and is caused by a western sedentary lifestyle with high calory diet in combination with susceptibility genes. Without lifestyle changes, available pharmaceutical treatments of T2D are only partially efficient. Recently, large scale allelic association analyses have begun to identify the genetic factors underlying susceptibility to T2D [1]. This new knowledge may permit unravelling of pathways leading to development of T2D and thereby aid in the development of more efficient prevention and therapy of this disease.

Liver X receptor alpha (LXRA, NR1H3) and beta (LXRB, NR1H2) are established sensors of lipid and cholesterol homeostasis [2]. Recently, a large body of literature has indicated a role of LXRs also in glucose metabolism and homeostasis. Several studies have demonstrated that LXR agonists reduce plasma glucose concentrations and increase insulin sensitivity in different models of diabetes and insulin resistance [3,4]. LXRs seem to improve glucose metabolism at different levels. In experimental models, LXR activation inhibits hepatic gluconeogenesis and glucose output [5,6]. Other results support that LXRs regulate peripheral glucose uptake. Activation of LXRs promotes glucose uptake and oxidation in muscle, and expression of the insulin responsive glucose transporter Glucose transporter type 4 (GLUT4) in adipocytes [5,7,8]. LXRs are also implicated in regulation of insulin secretion. Activation of LXRs increases glucose dependent insulin secretion in vitro from pancreatic beta-cell line cultures [9]. This effect may be mediated through LXRB since Lxrb-/- mice have lower basal insulin levels and are glucose intolerant due to impaired glucose induced insulin secretion [10]. Together, these observations point towards a physiological role of LXRs in glucose homeostasis.

We have previously reported that two LXRB SNPs associate with obesity in a Swedish cohort [rs35463555 (previously known as LB44732G>A), rs2695121, and marginally, rs17373080 (P value 0.06)] [11]. Furthermore, one LXRA SNP (rs11039155) was reported to associate with the metabolic syndrome in two French cohorts [12]. LXRA is encoded on human chromosome 11p11.2 and LXRB on chromosome 19q13.3.

Here we analyze if eight common SNPs in LXRA and LXRB associate with T2D in one French case-control cohort, and to phenotypes related to glucose homeostasis in two non-diabetic population-based cohorts comprising adult French and Swedish subjects. We also investigate the impact of one LXRB promoter SNP on gene transcription in vitro.

Methods
Subjects
The present study includes one large French cohort that was used for analysis of association between LXR gene SNPs and T2D. In addition, a subset of the non-diabetics in the French cohort, that is D.E.S.I.R., as well as the non-diabetics in the Swedish Stockholm Diabetes Prevention Program (SDPP) cohort, were analyzed for association between LXR SNPs and quantitative phenotypes related to glucose homeostasis. The cohorts used for quantitative trait analyses were population based. The study was approved by the ethical committee of the Karolinska University Hospital, the French National Commission for Informatics and Liberty and Hotel Dieu Ethics Committee. Informed written consent was received from all participants.

French cohort
The French T2D group included 988 unrelated T2D patients (N = 662 males and 326 females, age at examination 61.0 ± 10.2 years, BMI 26.3 ± 2.5 kg/m²) recruited at the Endocrinology-Diabetology Department of the Corbeil-Essonnes Hospital [13]. The type 2 diabetes status was defined according to the World Health Organization 1999 criteria [14]. The T2D patients included in the study were selected on a BMI < 30 kg/m² and all were unrelated. 346 T2D subjects were treated with insulin, 624 were treated with oral anti-diabetic drugs, and 18 subjects had other anti-diabetic treatment. The 941 control subjects were selected on fasting plasma glucose < 6.1 mmol/l and BMI < 27 kg/m² (N = 380 males and 561 females, age at examination 62.2 ± 7.5 years, BMI 23.2 ± 2.0 kg/m²) and all were unrelated. Of the 941 controls, 697 were selected from the D.E.S.I.R. general French population [15] and 244 were selected from the French families recruited at the CNRS unit in Lille. All subjects are of French Caucasian origin. We have compared the geno-
Figure 1
Schematic figure of LXRA and LXRB genes with position of genotyped SNPs according to NCBI as indicated.
typic distributions within the control group depending on the original selections. No significant difference was observed. For 1021 subjects (case and controls) of this study we could estimate the proportion of European ancestry from a previous genome-wide genotyping [16]. We performed logistic regression taking into account also the gender of the individuals, and observed at least 90% (in 1005 subjects) or 99% (in 835 subjects) of European ancestry (results below not included in the text). Thus, we can potentially exclude a possible stratification in the French study sample. Moreover, these results are supported by several other association studies [16-24]. Information about family history of T2D was available for the French family cohort and for most of the subjects that were included as controls there was no T2D in the ancestry. Family history of T2D was not available from the D.E.S.I.R. participants. The size of the French cohort provided 70% (90%) power to detect an allele with a frequency of 20% among controls and odds ratio (OR) 1.25 (1.35) to develop T2D assuming a threshold P value of 0.05 and dominant mode of inheritance (QUANTO, http://hydra.usc.edu/gxe/) [25].

Table 1: Analysis of association between LXR alleles and T2D in French cases vs control

| SNP     | Position | Allelea | #11b | #12 | #22 | %1c | %2 | rate | P valued | O.R. ± C.I.e |
|---------|----------|---------|------|-----|-----|-----|----|------|----------|-------------|
| LXRA    |          |         |      |     |     |     |    |      |          |             |
| rs4752822 | 5'       | T>C     | NDd  | 522 | 332 | 53  | 76 | 24   | 96       | 0.93        |
|          |          |         |      |     |     |     |    |      |          | 1.04 [0.89–1.21] |
|          |          |         |      |     |     |     |    |      |          |             |
| rs61896015 | intron 2 | C>A     | NDd  | 711 | 180 | 16  | 88 | 12   | 97       | 0.79        |
|          |          |         |      |     |     |     |    |      |          | 1.13 [0.93–1.37] |
|          |          |         |      |     |     |     |    |      |          |             |
| rs1221497 | intron 2 | G>A     | NDd  | 718 | 180 | 17  | 88 | 12   | 97       | 0.69        |
|          |          |         |      |     |     |     |    |      |          | 1.09 [0.90–1.33] |
|          |          |         |      |     |     |     |    |      |          |             |
| rs2279239 | intron 4 | T>C     | NDd  | 518 | 328 | 52  | 76 | 24   | 97       | 0.94        |
|          |          |         |      |     |     |     |    |      |          | 1.03 [0.89–1.20] |
|          |          |         |      |     |     |     |    |      |          |             |
| rs2279238 | exon 5   | C>T     | NDd  | 715 | 195 | 12  | 88 | 12   | 98       | 0.62        |
|          |          |         |      |     |     |     |    |      |          | 0.99 [0.81–1.2] |
|          |          |         |      |     |     |     |    |      |          |             |
| LXRB    |          |         |      |     |     |     |    |      |          |             |
| rs35463555 | promoter | G>A     | NDd  | 417 | 388 | 106 | 67 | 33   | 96       | 0.74        |
|          |          |         |      |     |     |     |    |      |          | 0.94 [0.82–1.08] |
|          |          |         |      |     |     |     |    |      |          |             |
| rs17373080 | promoter | C>G     | NDd  | 411 | 386 | 104 | 67 | 33   | 96       | 0.42        |
|          |          |         |      |     |     |     |    |      |          | 0.94 [0.82–1.08] |
|          |          |         |      |     |     |     |    |      |          |             |
| rs2248949 | intron 6 | C>T     | NDd  | 310 | 432 | 139 | 60 | 40   | 93       | 0.05        |
|          |          |         |      |     |     |     |    |      |          | 1.02 [0.90–1.17] |

a) Common allele is written first. b) #11 = number of subjects homozygous for common allele, #12 = number of heterozygous subjects, #22 = number of subjects homozygous for rare allele. c) Major allele frequency. d) HWE P values were calculated in HAPLOVIEW [32]. e) O.R. ± C.I. = odds ratio ± confidence intervals. ORs were calculated as (number allele 2 among cases * number allele 1 among controls)/(number allele 1 among cases * number allele 2 among controls). f) Pearson’s Chi² (d.f. = 1) was used to compare allele frequencies between T2D-cases and controls. g) ND = non-diabetic controls, T2D = type 2 diabetes
Swedish cohort

For the Swedish SDPP study, a short questionnaire was sent to all men born between 1938 and 1957 living in four municipalities in the outskirts of Stockholm and all women born between 1942 and 1961 living in the same municipalities and one additional municipality, asking about country of birth and presence of diabetes in subjects and relatives. Persons were excluded as a result of diabetes and foreign origin. In a second step, subjects with family history of diabetes, together with subjects randomly selected from those without family history of diabetes, matched to the first group by age and municipality were invited to a health examination. Subjects with DNA available were included in this study.

SDPP included 1024 normoglycemic controls with normal glucose tolerance (N = 778 males and 246 females, age at examination 46.7 ± 4.9 years, BMI 25.5 ± 4.4 kg/m²) and 320 subjects with impaired glucose tolerance (IGT) (N = 174 males and 146 females, age at examination 48.2 ± 4.5 years, BMI 29.2 ± 5.3 kg/m²) [26-29].

The size of the population-based non-diabetic Swedish SDPP and French D.E.S.I.R. cohorts together provided 53% (98%) power to detect an allele with a frequency of 15% and marginal β = 0.2 (0.4) for HOMA IR as measure of insulin resistance, assuming a threshold P value of 0.05 and dominant mode of inheritance (QUANTO, http://hydra.usc.edu/gxe/) [25].

Clinical evaluation

In the morning a fasting venous blood sample was obtained for determination of fasting levels of insulin and glucose by the routine chemistry laboratory of the hospitals, and for extraction of DNA using standard protocols. An oral glucose tolerance test was performed in the SDPP subjects. Diabetes was defined according to the World Health Organization 1999 criteria: fasting plasma glucose

Table 2: Association of LXRB promoter SNP genotypes with T2D in the French cohort

| SNP       | Recessive | Dominant |
|-----------|-----------|----------|
|           | O.R.+C.I. | P value  | O.R.+C.I. | P value  |
| rs35463555 | 1.310 [0.955–1.798] | 0.09     | 1.356 [1.003–1.834] | 0.047   |
| rs1737080  | 1.360 [0.986–1.875] | 0.06     | 1.416 [1.042–1.924] | 0.026   |

1 = common allele, 2 = rare allele 
OR: homozygous/recessive: (Case_11*Control_22)/(Case_22*Control_11), allele positivity/dominant: ((Case_12+Case_11)*Control_22)/ (Case_22*(Control_12+Control_11))

Table 3: Analysis of LXR haplotypes in T2D in the French cohort

| Block          | Specific haplotype (%) | Case | Controls | P Value |
|----------------|------------------------|------|----------|---------|
| LXRA: rs47552822- rs61896015- rs12221497- rs2279239- rs2279238 | TCGTC | 75.1 | 75.9 | 0.56 |
|                | CAACC                   | 13.1 | 12.0 | 0.32 |
|                | CCGC                    | 11.8 | 12.1 | 0.80 |
| LXRB: rs35463555- rs1737080- rs2248949 | GCT  | 41.0 | 40.6 | 0.81 |
|                | AGC                     | 31.7 | 33.0 | 0.41 |
|                | GCC                     | 27.2 | 26.4 | 0.55 |

Haplotype frequencies in cases versus controls are compared by Chi² test. Counts for association tests are obtained by summing the fractional likelihoods of each individual for each haplotype.

Figure 2

Linkage disequilibrium between LXRA and LXRB SNPs as indicated. Shown are r²-values. D’ was 1.00 between all SNPs within each gene.
≥ 7.0 mmol/l and/or 2-h plasma glucose ≥ 11.1 mmol/l, or ongoing treatment with oral antidiabetic agents and/or insulin [14]. IGT was defined as fasting plasma glucose < 7.0 mmol/l and 2-h plasma glucose 7.8–11.0 mmol/l. Insulin resistance index HOMAIR (homeostasis model assessment) was calculated as fasting serum insulin (μU/ml) × fasting plasma glucose (mmol/l)/22.5 [30]. The diagnosis of T2D as opposed to type 1 diabetes was based on clinical records and judgment by the investigating physicians.

**SNP selection and genotyping**

We genotyped altogether five SNPs in the LXRA gene (Figure 1A). Three of the genotyped LXRA SNPs cover the common variation in this gene in a French cohort according to Legry et al [12]. According to Legry et al a, LXRA comprises three common haplotypes, which are tagged by SNPs genotyped in the present study. We were unable to design a multiplex assay including the SNP rs11039155, which in French cohorts has been associated with the metabolic syndrome. However, we genotyped instead rs2279238 that is in complete linkage disequilibrium (LD) with rs11039155 [12]. Since the SNPs genotyped by Legry did not fully cover the two untranslated 5' exons of LXRA we added two more SNPs in this region from our previous study of LXRA in obesity, that is rs4752822 and rs61896015 (the latter previously labelled LA9462C>A) [11]. For LXRB, we genotyped three SNPs that covered 57% of alleles as r2 ≥ 0.80 according to our own sequencing and genotyping of the gene in a Swedish cohort (Figure 1B) [11]. The reason for the relatively low coverage was that we were unable to select and genoty whole 5' exons of LXRA we added two more SNPs in this region from our previous study of LXRA in obesity, that is rs4752822 and rs61896015 (the latter previously labelled LA9462C>A) [11]. For LXRB, we genotyped three SNPs that covered 57% of alleles as r2 ≥ 0.80 according to our own sequencing and genotyping of the gene in a Swedish cohort (Figure 1B) [11]. The reason for the relatively low coverage was that we were unable to design a high throughput genotyping assay for two variations; a repeat and a SNP located in this repeat. The three SNPs cover the three common LXRB gene haplotypes according to our own previous genotyping of this gene in a Swedish cohort [11].

| French | T2D cases |
|--------|-----------|
| all    | females   | males   |
| number | 988       | 326     | 662     |
| Age (year) | 61.0 ± 10.2 | 62.8 ± 10.7 | 60.1 ± 9.9 |
| BMI (kg/m²) | 26.3 ± 2.5 | 26.0 ± 2.8 | 26.4 ± 2.3 |
| fP-Glucose (mmol/l) | NA | NA | NA |
| fS-Insulin (pmol/l) | NA | NA | NA |
| HOMAIR | NA | NA | NA |

| French | Normoglycemic controls |
|--------|------------------------|
| D.E.S.I.R. | From the CNRS unit in Lille |
| all | females | males | all | females | males |
| number | 697 | 419 | 278 | 244 | 142 | 102 |
| Age (year) | 53.4 ± 5.6 | 53.2 ± 5.7 | 53.8 ± 5.6 | 60.9 ± 10.5 | 61.2 ± 10.9 | 60.6 ± 10.0 |
| BMI (kg/m²) | 23.2 ± 1.8 | 22.8 ± 1.7 | 23.9 ± 1.7 | 23.0 ± 2.8 | 22.4 ± 3.1 | 23.7 ± 2.0 |
| fP-Glucose (mmol/l) | 5.1 ± 0.4 | 5.0 ± 0.4 | 5.2 ± 0.3 | 5.0 ± 0.4 | 5.0 ± 0.4 | 5.2 ± 0.4 |
| fS-Insulin (pmol/l) | 5.1 ± 3.7 | 4.9 ± 2.3 | 5.3 ± 5.2 | 7.4 ± 5.2 | 7.1 ± 4.6 | 7.7 ± 5.9 |
| HOMAIR | 1.3 ± 0.6 | 1.3 ± 0.6 | 1.4 ± 0.7 | 1.7 ± 1.2 | 1.6 ± 1.0 | 1.8 ± 1.4 |

| Swedish | SDPP |
|--------|------|
| Normoglycemic controls | Impaired glucose tolerance |
| number | 1024 | 246 | 778 | 320 | 146 | 174 |
| Age (year) | 46.7 ± 4.9 | 47.0 ± 4.6 | 46.6 ± 5.0 | 48.2 ± 4.5 | 48.6 ± 4.4 | 48.0 ± 4.6 |
| BMI (kg/m²) | 25.5 ± 4.4 | 22.6 ± 1.7 | 26.5 ± 4.5 | 29.2 ± 5.3 | 29.2 ± 6.0 | 29.2 ± 4.6 |
| fP-Glucose (mmol/l) | 4.6 ± 0.5 | 4.5 ± 0.4 | 4.7 ± 0.6 | 5.3 ± 0.7 | 5.2 ± 0.6 | 5.5 ± 0.7 |
| fS-Insulin (pmol/l) | 180 ± 10.2 | 92 ± 3.6 | 207 ± 10.0 | 220 ± 11.8 | 156 ± 7.6 | 271 ± 12.1 |
| HOMAIR | 3.7 ± 2.3 | 1.8 ± 0.8 | 4.3 ± 2.3 | 5.2 ± 3.2 | 3.5 ± 2.1 | 6.6 ± 3.2 |
| 2 h P-Glucose (mmol/l) | 4.5 ± 1.2 | 4.1 ± 1.0 | 4.7 ± 1.3 | 8.7 ± 1.0 | 8.8 ± 0.8 | 8.7 ± 1.1 |

Values are mean ± SD. NA = not available.
Both samples were genotyped using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry [31]. Primers are provided on request. Due to initial low call rate, rs2248949 was re-genotyped by Taqman in a subset of the Swedish cohort (C_1993248_20, Applied Biosystems, Foster City, CA, USA). The final genotype call rate was ≥ 93% for all SNPs. The accuracy was 99.99% according to duplicate analysis of, on average, 2% of the total genotypes. Hardy-Weinberg equilibrium (HWE) calculations were performed in Haploview to ensure that each marker was within population equilibrium [32].

Cloning of the LXRB promoter into reporter vectors and in vitro mutagenesis

The -244/+1163 sequence of the human LXRB gene was cloned into the pGL3 basic luciferase reporter vector (Promega) using the Kpn I and Mlu I sites applying primers 5'-ATCAGGTACCCGCCGAGGCCGCTCAAGAAGCAGCAGTGAATGAGCTAA-3' and 5'-ATCACCTGAGGTGAGGGTCACGGAGCAGCCTGTAGAATACAGGGGATTGGAG-3' with the restriction enzyme sites underlined. The G allele (bold) of rs17373080 was generated using the following primer (5'-TAAAGCAGAAGCAGCGGGCTGGAGTTT-3' using the QuikChange® XI Site-Directed Mutagenesis Kit (Stratagene). DNA sequencing confirmed the identity of all clones.

Table 5: LXR genotypes in the Swedish population based SDPP cohort

| SNP   | Allele | #11 | #12 | #22 | %11 | %12 | %22 | %1c | %2 | call rate % | HWE P value |
|-------|--------|-----|-----|-----|-----|-----|-----|-----|----|-------------|-------------|
| LXRA  |        |     |     |     |     |     |     |     |    |             |             |
| rs4752822 | T>C  | 570 | 605 | 157 | 43  | 45  | 12  | 66  | 34 | 99          | 0.91        |
| rs61896015 | C>A  | 886 | 377 | 47  | 68  | 29  | 4   | 82  | 18 | 97          | 0.42        |
| rs12221497 | G>A  | 902 | 370 | 47  | 68  | 28  | 4   | 82  | 18 | 98          | 0.27        |
| rs2279239  | T>C  | 559 | 590 | 151 | 43  | 45  | 12  | 66  | 34 | 97          | 0.86        |
| rs2279238  | C>T  | 923 | 360 | 35  | 70  | 27  | 3   | 84  | 16 | 98          | 1.00        |
| LXRB    |        |     |     |     |     |     |     |     |    |             |             |
| rs35463555 | G>A  | 612 | 576 | 140 | 46  | 43  | 11  | 68  | 32 | 99          | 0.86        |
| rs17373080 | C>G  | 613 | 578 | 137 | 46  | 43  | 11  | 68  | 32 | 99          | 1.00        |
| rs2248949 | C>T  | 426 | 607 | 267 | 33  | 47  | 20  | 56  | 44 | 97          | 0.07        |

a) Common allele is written first. b) #11 = number of subjects homozygous for common allele, #12 = number of heterozygous subjects, #22 = number of subjects homozygous for rare allele. c) Major allele frequency. d) HWE P values were calculated in HAPLOVIEW [32].

**Transient transfections**

The mouse pancreatic beta-cell line MIN6 was maintained in Dulbecco's modified Eagle's medium (DMEM, 4.5 g/L glucose, 41965-039), the human hepatoma cell line HuH7 was grown in DMEM with 0.11 g/L NaPyr (41966-029), and African green monkey kidney cells Cos7 in DMEM with 1 g/L glucose (31885-023). All media were from GibCO-BRL. The cell lines were supplemented with fetal bovine serum (Cos7, HuH7: 10%, MIN6: 15%), 2 mM L-glutamine (only MIN6), and penicillin/streptomycin at a final concentration of 100 U/ml and 100 μg/ml, respectively. Additionally, 50 μM β-mercaptoethanol was added to the MIN6 cells. Cells were grown under 5% CO2 at 37°C. Approximately 4 x 10⁴ cells per well were plated in 24 well plates and transiently transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. Each well received 50 ng of reporter vector and 125 ng of expression vector, respectively. Vehicle vector was added to ensure equal amounts of DNA in each transfection. Cells were transfected for 24 h and thereafter lysed in 25 mM TAE, 1 mM EDTA, 10% glycerol, 1% Triton X-100, and 2 mM DTT. Luciferase activities were measured using a Luciferase Assay Kit (BioThema, Umeå, Sweden) in a luminometer (Luminoscan Ascent, Thermo electron Corporation, Waltham, MA). The NF1 transcription factors were cloned into the pCH-expression vectors and were a kind gift of Dr. Gronostajski, Cleveland Clinic Foundation Research Institute.
**Figure 3**

**A**. Schematic view of the reporter gene construct driven by the endogenous -244/+1163 LXRB gene region. The black dot indicates rs17373080. **B**. Basal activities of the -244/+1163 rs17373080 G allele and C allele reporter constructs. Using in vitro mutagenesis with the G allele construct as a template a new C allele construct was generated. The results presented are mean differences of more than 20 independent transfection experiments. The activities of the G allele in each cell line analyzed were set to 100% ± SEM. * P < 0.05 by Student’s t test.

**Whole cell extracts**

MIN6 cells were grown to confluence in 100 mm dishes, washed with PBS and incubated in TEN buffer (40 mM Tris-HCl, 1 mM EDTA, 150 mM NaCl) for 4 min. Cells were then removed with a cell scraper and pelleted by centrifugation at 3,500 rpm for 2 min at 4°C. Cell pellets were then removed with a cell scraper and pelleted by centrifugation at 13,000 rpm for 5 min at 4°C. The supernatant corresponds to MIN6 whole cell extracts. The genetic models analyzed by the Finetti software were defined as homozygous/recessive: (Case_11*Control_22)/(Case_22*Control_11) and allele positivity/dominant: ((Case_12+Case_11)*Control_22)/(Case_22*(Control_12+Control_11)). To take into account the impact of gender on susceptibility to T2D, we used logistic regression with genotype and sex as independent variables. Haploview was used to calculate LD between SNPs (D' and r²), estimate haplotypes, and to test for association between haplotypes and T2D [32]. The program Thesias was used to test two-by-two sliding window SNPs haplotypes [34]. This program determines both the haplotype frequency and its effect on the phenotype through an estimation-maximisation algorithm. In this analysis, we also considered gender as a covariate.

**Electro mobility shift assay (EMSA)**

The oligo including a consensus site for nuclear factor 1 (NF1) is 5'GATCTTATTTTGGATTGAAGCCAATATGAG-3'. The rs17373080 C allele oligo is 5'-GCCTAAAGCGCGGGG-3' with G allele in bold. The rs17373080 G allele oligo is 5'-GCCTAAAGCGCGGGG-3' with G allele in bold. 5.0 μg of the respective forward and reverse oligos were annealed in 20 mM Tris-HCl pH 7.8; 2 mM MgCl₂; 50 mM NaCl by heating to 95°C for 5 min and slow cooling by 1.5°C/minute for 47 cycles. Oligonucleotide probes were labeled by mixing 0.2 μg annealed oligo with 250 μM non-radioactive dATP, dGTP, dTTP, respectively, 1× Klenow buffer, 20 μCi 32P-labeled dCTP (Amersham Pharmacia) and 1 Unit Klenow polymerase. Samples were incubated for 20 min at room temperature. Reactions were stopped by adding 0.5 M EDTA. Probes were purified using G-25 Nick Columns (Amersham Pharmacia) and the efficiency of labeling determined using the 1214 Rackbeta liquid scintillation counter (LKB Wallac). For binding reactions, 5 μl of MIN6 whole cell extracts were incubated with 4 × 10⁴ cpm of radiolabeled oligonucleotide in binding buffer (4 μg BSA, 2 μg poly dI-dC, 12 mM HEPES (pH 7.9), 12% glycerol, 0.12 mM EDTA, 0.9 mM MgCl₂, 0.6 mM dithiothreitol, 0.6 mM phenylmethylsulfonyl fluoride). Binding reactions were incubated for 20 min at RT, electrophoresed at 150 V for 3 h in 6% polyacrylamide gels at 4°C, dried and finally analyzed by autoradiography. In competition assays, the unlabeled competitor was added prior to the nuclear extracts.

**Statistical analyses**

The Finetti software and Pearson’s Chi² (d.f. = 1) were used to compare allele and genotype frequencies between cases and controls and to calculate odds ratios (OR) [33]. The genetic models analyzed by the Finetti software were defined as homozygous/recessive: (Case_11*Control_22)/(Case_22*Control_11) and allele positivity/dominant: ((Case_12+Case_11)*Control_22)/(Case_22*(Control_12+Control_11)). To take into account the impact of gender on susceptibility to T2D, we used logistic regression with genotype and sex as independent variables. Haploview was used to calculate LD between SNPs (D' and r²), estimate haplotypes, and to test for association between haplotypes and T2D [32]. The program Thesias was used to test two-by-two sliding window SNPs haplotypes [34]. This program determines both the haplotype frequency and its effect on the phenotype through an estimation-maximisation algorithm. In this analysis, we also considered gender as a covariate.

ANCOVA with SNP genotypes and gender as main effects and age, and when appropriate BMI, as simple regressor was used to analyze differences in HOMA IR, fasting plasma glucose, serum insulin, and BMI between LXR genotypes in the non-diabetic population-based cohorts, SDPP and normoglycemic non-obese samples from the D.E.S.I.R. respectively. The analyses were repeated in joint analyses of both cohorts including cohorts as an additional main effect. 2-h plasma glucose was available and analyzed as above in the Swedish cohort only. Quantitative phenotypes were normalized by natural logarithm transformation before analysis to become normally dis-
A. A putative NF1 binding site in the promoter region of the LXRB gene as suggested by TESS (underlined) [36]. The rs17373080 SNP is indicated in bold. B. EMSA with MIN6 whole cell extracts (WCE) and labelled oligonucleotides with the rs17373080 C and G variants, respectively. Lane 1: Free oligo C, 2: Oligo C + MIN6 WCE, 3–5: Oligo C + MIN6 WCE + increasing amounts of unlabeled NF1 consensus oligonucleotide, 6: Empty 7: Free oligo G, 8: Oligo G + MIN6 WCE, 9–11: Oligo G + MIN6 WCE + increasing amounts of unlabeled NF1 consensus oligonucleotide. C. EMSA with rs17373080 SNP oligo C and MIN6 whole cell extract or in vitro translated (IVT) NF1. Lane 1: Free oligo C, 2: Oligo C + MIN6 whole cell extract, 3: Oligo C + MIN6 whole cell extract + 250× unlabeled NF1 consensus oligonucleotide, 4: Oligo C + Empty IVT expression vector (vehicle) and 5–7: Oligo C + IVT NF1A1, NF1B and NF1X, respectively. The arrows indicate the positions of the NF1 interactions.
tributed. In the transient transfections functional studies the student's t-test was applied.

Results

Analysis of association between LXR gene SNPs and T2D

We first analyzed LXR gene SNPs for association with T2D in the French case-control cohort. Altogether we genotyped five LXRA SNPs and three LXRB SNPs. All SNPs had a call rate of ≥ 93% and were in HWE in the French cohort (Table 1). We analyzed LXR SNPs for association with T2D under different genetic models. No SNP allele associated to T2D (Table 1). However, genotype at the LXRB promoter SNPs rs35463555 and rs17373080 associated nominally to T2D assuming a dominant T2D-predisposing common allele, P value 0.047 and 0.026 respectively (Table 2). This was due to an increased risk of T2D among heterozygous and protection against T2D among subjects homozygous for the rare allele (Table 1). None of analyzed SNPs showed significant association with T2D when taking into account the gender effect. SNPs within LXRA and LXRB were in strong LD and together built one haplotype for the respective genes (Figure 2). No LXRA and no LXRB haplotype associated with T2D (Table 3). Furthermore, no two-by-two sliding window SNPs haplotypes associated with T2D (results not shown).

Analysis of association between LXR SNPs and quantitative phenotypes reflecting glucose homeostasis

We next analyzed LXR gene SNPs for impact on quantitative phenotypes related to glucose homeostasis in non-diabetic subjects. For this purpose, we analyzed the normoglycemic non-obese population-based samples selected from the French D.E.S.I.R. cohort and the Swedish SDPP cohort. Phenotypes of these cohorts are shown in Table 4. In the Swedish cohort an oral glucose tolerance test was performed and the analyzed cohort included 320 subjects with IGT. Genotyping result for the D.E.S.I.R. samples is included in the controls in Table 1. Genotype results for SDPP are shown in Table 5. All SNPs had call rates ≥ 96%. All SNPs were in HWE. Allele frequencies for LXRB SNPs were almost identical in the Swedish and French cohorts whereas allele frequencies for LXRA SNPs differed 4–10% between the populations. LXR SNPs had no impact on fasting plasma glucose or serum insulin, insulin resistance measured as HOMA_B or BMI in either the D.E.S.I.R. or the SDPP cohort, nor in the joint analysis of both cohorts (results not shown). Nor did LXR SNPs associate to the response to an OGTT in SDPP (results not shown).

Functional analysis of the LXRB rs17373080 SNP

The C allele of rs17373080 associates with higher transcription activity in vitro

We have previously determined the transcription start site of the human LXRB gene promoter [35]. The LXRB SNP rs17373080 is located in the proximal promoter close to the transcription start site and could potentially have an impact on the transcription potential of the LXRB gene promoter. Hence we performed functional studies investigating this SNP. The -244/+1163 gene region including the rs17373080 with either the C or the G allele was PCR cloned in front of the luciferase gene reporter (Figure 3A). Otherwise the promoters were identical. The activities of the two different alleles were analyzed in transient transfection assays in three different cell lines. There was a sig-
nificantly higher basal activity for the C allele in all three cell lines investigated (Figure 3B) indicating that the C allele is able to maintain a higher basal transcription of the LXRB gene.

A functional NF1 binding site overlaps rs17373080

A theoretical search for transcription factor binding sites using the transcription element search system (TESS) suggested a binding site for the NF1 transcription family members overlapping the rs17373080 position (Figure 4A) [36]. The different alleles were tested for interaction with NF1 using direct DNA binding and transactivation assays. The DNA-mobility shift assay indicated equal binding of components in whole cell extracts to oligonucleotides corresponding to the C and G alleles, respectively (Figure 4B, lanes 2 and 8) and the DNA-protein interaction was competed away by increasing amounts of an unlabelled NF1 consensus binding site (lanes 3–5 and 9–11). NF1A1, NF1B and NF1X produced by in vitro transcription/translation gave protein-DNA complexes of the same size as that produced by whole cell extracts (results not shown). Different NF1 family members (NF1A1, NF1B, NF1C and NF1X) showed different transactivation capacity on the LXRB gene promoter (Figure 5). However, no difference in induced transactivation activity of the NF1s was observed between the G (Figure 5A) and C (Figure 5B) promoter alleles.

Discussion

We have analyzed common genetic variation in LXRA and LXRB for association with T2D in one French cohort and for association with quantitative measures of glucose homeostasis in two non-diabetic population-based samples from France and Sweden. Genotype at the LXRA promoter SNPs rs17373080 and rs35463555 nominally associates to T2D. rs17373080, which regulates transcription in vitro, may directly affect the risk of developing T2D whereas the association between T2D and rs35463555, which is located in a repeat, could be due to strong LD with 17373080. No LXRA SNPs associate to the investigated phenotypes.

We have previously reported that LXRB SNPs associate with obesity in a Swedish cohort [rs35463555 (previously known as LB44732G>A), rs2695121, and marginally, rs17373080 (P value 0.06)] [11]. The genotype at rs35463555 and rs17373080 predisposing to obesity in the previous study was found to also associate to T2D in this study. The association between rs35463555, rs17373080 and T2D reported here would become non-significant following Bonferroni-correction for analysis of several LXR SNPs and phenotypes. However, since our results are confirmatory in nature, that is the rs35463555 and, marginally, rs17373080 SNPs have previously been associated with another metabolic phenotype, namely obesity, we think it is too stringent to perform Bonferroni correction. Similarly, since analysed phenotypes are dependent, Bonferroni correction may be too stringent. On the other hand, it is important to note that observed association P values for rs35463555 and rs17373080 (0.047 and 0.026) are weak and would become non-significant following adjustment for just two independent analyses. We did not observe any association between LXRB SNPs and BMI in this study. This may be due to phenotypic differences between cohorts. The population-based cohorts D.E.S.I.R. and SDPP that we analyzed here contain markedly less obese people than the previous Swedish study. Together, previous and present results support that LXRB promoter genotype regulates susceptibility to adiposity as well as T2D. However, replications of these associations in additional large cohorts are necessary before establishing an association between LXRB genotype, obesity and T2D. Published genome wide association studies of T2D have not reported association with LXR genes [16-24,37-39]. However, it is uncertain to what extent these studies cover the rather small LXRA and LXRB genes since the full datasets are unavailable. In the French cohort, gender distribution was the opposite in T2D cases versus controls. The main concern with different gender distribution in cases and controls is reduced power to identify T2D genes due to gender impact on T2D susceptibility and potential gene-gender interaction.

An LXRB promoter SNP could contribute to development of T2D by altering mRNA levels of LXRB in one or more of the organs regulating glucose homeostasis; LXRB is expressed in pancreas, liver, muscle, as well as adipose tissue [40]. It has recently been reported that LXRB is the main LXR paralogue in pancreatic beta-cells, that activated LXR induces insulin secretion from beta-cells and that mice lacking the Lxrb gene have less glucose stimulated insulin secretion [9]. The T2D-associated LXRB promoter SNP rs35463555 is located in a large repeat region of ~2500 base pairs and is therefore difficult to clone and study functionally. An in silico search using TESS revealed no binding sites for human transcription regulators covering rs35463555 [36]. Therefore, we did not perform any functional studies of this SNP. As for the proximal LXRB promoter SNP rs17373080, according to our results the GG genotype protected against T2D whereas the G allele showed reduced reporter gene activity, which suggests that the G allele is associated with lower LXRB mRNA levels. Thus, these results are contrary to what one would expect based on the results in the Lxrb knock-out mice. However, rs17373080 may regulate overall glucose homeostasis through other mechanisms and in other organs in humans.

We observed that the rs17373080 SNP overlapped an NF1 site. The NF1 site was functional in recruiting NF1. How-
ever, we did not observe any differences between the G and C alleles in DNA-binding and transactivation of a reporter gene by NFI family members. It cannot be excluded that rs17373080 overlaps additional transcription factor binding sites and that the binding and/or activity of these sites is affected by the various rs17373080 alleles. It might also be that the differences between the C and G alleles with regard to transcription factor-induced transcription activity are too subtle to be detected with existing methods. However, our results indicate that the transcriptional activity of NFI could be tissue or cell specific as similar results were observed in Cos7 and MIN6 cells, but not in HuH7 cells. Speculatively, these results could suggest that the relevance of the SNP rs17373080 in developing T2D could be tissue specific and further studies should be focusing on the role of LXRβ in these cell types where NFI was shown to affect the transcription rate of the LXRβ gene.

There was no association between SNPs covering the common variation in LXRα and susceptibility to T2D or levels of plasma glucose, serum insulin, and insulin resistance measured as HOMAIR. According to power calculations of plasma glucose, serum insulin, and insulin resistance common genetic variation in rs17373080 may regulate susceptibility to T2D, whereas that the impact of LXRβ on these phenotypes and it is therefore unlikely that this gene directly regulates glucose homeostasis. We did not have access to blood lipids in the SDPP cohort. This prohibited us from determining which subjects fulfilled the criteria for the metabolic syndrome and measures of glucose homeostasis reported here, that the impact of LXRα on susceptibility to the metabolic syndrome is mediated via an impact on lipid turnover rather than glucose homeostasis [12].

Conclusion
The common LXRβ promoter SNPs rs35463555 and rs17373080 may regulate susceptibility to T2D, whereas common genetic variation in LXRα is unlikely to affect the risk of developing T2D or quantitative phenotypes related to glucose homeostasis. The association between LXRβ rs35463555 and rs17373080 and T2D needs to be investigated in additional large cohorts.

Competing interests
Jan-Åke Gustafsson is consultant, shareholder and research grant receiver of KaroBio AB. The other authors declare that they have no competing interests.

Authors’ contributions
ID analyzed the data and wrote the manuscript. MN designed the study and performed the in vitro studies. HFG, MV and CL participated in the design of the study, data analysis, and in the writing of the manuscript. CCP, SE, CGO, KB, GC and PF ascertained the patient cohorts. JÅG helped to draft the manuscript. KDW and KRS designed the study and helped to draft the manuscript. All authors have read and approved the final manuscript.

Acknowledgements
This work was supported by The Swedish Diabetes Association, the Royal Physiographic Society in Lund, Stiftelsen Lars Hiertas Minne (both to MN), and the Swedish Research Council. We wish to thank Dr Beverly Balkau and the D.E.S.I.R. Study group for providing a proportion of the French normoglycemic control samples and phenotype data; and Dr Guillaume Charpentier from the Department of Endocrinology-Diabetology, Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France for his continuous support and collaboration in the recruitment of the diabetic patients.

References
1. Frayling TM, McCarthy MI: Genetic studies of diabetes following the advent of the genome-wide association study: where do we go from here? Diabetologia 2007, 50(11):2229-2233.
2. Zelcer N, Tontonoz P: Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006, 116(3):607-614.
3. Cao G, Liang Y, Broderick CL, Oldham BA, Beyer TP, Schmidt RJ, Zhang Y, Stayrook KR, Suen C, Otto KA, et al.: Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. J Biol Chem 2003, 278(2):1113-1116.
4. Grether JF, van Dijk TH, Hammer A, Slujs FH van der, Havening R, Havekes LM, Romsij JA, Groot PH, Reijnoudt DJ, Kuijpers P: Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. Am J Physiol Endocrinol Metab 2005, 289(5):E829-838.
5. Laffitte BA, Chao LC, Li J, Walczak R, Hummasti S, Joseph SB, Castirillo A, Wilpitz DC, Mangelsdorf DJ, Collins JL, et al.: Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci USA 2003, 100(9):5419-5424.
6. Che JF, Repa JJ: The Liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J Biol Chem 2007, 282(1):743-751.
7. Kase ET, Wensaas AJ, Aas V, Hojlund K, Levin K, Thoresen GH, Beck-Nielsen H, Rustan AC, Gaster M: Regulation of the insulin-responsive glucose transporter GLUT4 in adipocytes is dependent on liver X receptor alpha gene polymorphisms and risk of metabolic syndrome. Diabetes 2004, 53(Suppl 3):S75-78.
8. Gerin I, Dolinsky YW, Shackman JG, Kennedy RT, Chiang SH, Burant CF, Steffensen KR, Gustafsson JA, MacDougald OA: LXRbeta is required for adipocyte growth, glucose homeostasis, and beta cell function. J Biol Chem 2005, 280(24):23024-23031.
9. Dahlman I, Nilsson M, Jiao H, Hoffstedt J, Lindgren CM, Humphreys K, Kere J, Gustafsson JA, Arner P, Dahlman-Wright K: Liver X receptor gene polymorphisms and adipose tissue expression levels in obesity. Pharmacogenet Genomics 2006, 16(12):881-889.
10. Legry V, Cottel D, Ferrieres J, Chineti G, Deroide T, Staels B, Amouyel P, Meirhaeghe A: Association between liver X receptor alpha gene polymorphisms and risk of metabolic syndrome in French populations. Int J Obes (Lond) 2008, 32(3):421-428.
11. Cheyssac C, Lecoeur C, Dechaume A, Bibi A, Charpentier G, Balkau B, Marre M, Froger P, Gibson M, Vaxillaire M: Analysis of common PTPN1 gene variants in type 2 diabetes, obesity and associated phenotypes in the French population. BMC Med Genet 2006, 7:44.
14. World Health Organization Report: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Definition and classification of diabetes mellitus. Report of WHO consultation. 1999 [http://whqlibdoc.who.int/hq/1999/]

15. Vaxillaire M, Veslot J, Dina C, Poenca C, Cauchi S, Charpentier G, Tichert J, Fumeron F, Marre M, Meyre D, et al.: Impact of common type 2 diabetes risk polymorphisms in the DESIR prospective study. Diabetes 2008, 57(1):244-254.

16. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent C, Belisle A, Hadjadj S, et al.: A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007, 445(7130):881-885.

17. Florez JC, Mitrani AK, Dupuis J, Mahtje J, Irenze K, Gianniny L, Mirel DB, Fox CS, Cupples LA, Meigs JB: A 100K genome-wide association scan for diabetes and related traits in the Framingham Heart Study: replication and integration with other genome-wide datasets. Diabetes 2007, 56(12):3063-3074.

18. Steinthorsdottir V, Thorleifsson G, Reynisdottir I, Benediktsson R, Ingelsson E, Ouwehand W, Strom L, Ostenson CG, Grill V: Weight history, glucose intolerance and insulin levels in middle-aged Swedish men. Diabetes Care 2008, 31(5):1098-1104.

19. Hayes MG, Plaznikov A, Miyake K, Sun Y, Ng MC, Roe CA, Below JE, Nicolaie RL, Konakshabaei A, Bell GL, et al.: Identification of type 2 diabetes genes in Mexican Americans through genome-wide association studies. Diabetes 2007, 56(12):3033-3044.

20. Rampersaud E, Damcott CM, Fu M, Shen H, McCardle P, Shi X, Shelton J, Yin J, Chang YP, Qin SH, et al.: Identification of novel candidate genes for type 2 diabetes from a genome-wide association scan in the Old Order Amish: evidence for replication from diabetes-related quantitative traits and from independent populations. Diabetes 2007, 56(12):3053-3062.

21. Salonen JT, Uimari P, Aalto JM, Pirskanen M, Kaikkonen J, Todorova MB, Monauni T, Muggeo M: Measurement of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000, 23(1):57-63.

22. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Duren WL, Shi X, Li Y, Duren WL, et al.: A genomewide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007, 316(5829):1341-1345.

23. Steinthorsdottir V, Thorleifsson G, Reynolds G, Benediktsrsson R, Jonsdottir T, Walters GB, Styrkarsdottir U, Grettarsdottir S, Emilsson V, Ghosh S, et al.: A variant in C6orf164 influences insulin response and risk of type 2 diabetes. Nat Genet 2007, 39(11):1340-1345.

24. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Laitinen T, Liu Q, Mathias RA, Perry J, Clayton DG, et al.: Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007, 316(5829):1336-1341.

25. Guo A, Morrison J, Wu J, Wallace H, Guo J, Zeggini E, Scott L, Saxena R, Voight BF, Marchini JL, Hu T, de Bakker PJ: A new algorithm for haplotype-based association analysis: the StatisticEM algorithm. Ann Hum Genet 2004, 68(2 Pt 2):165-177.

26. Nilsson M, Dahlman-Wright K, Karelmo C, Ebeling M, Gustafsson JA, Steffen KM, Elki and SRF transcription factors convey basal transcription and mediate glucose response via their binding sites in the human LXRbeta gene promoter. Nucleic Acids Res 2007, 35(14):4858-4868.

27. Tregouet DA, Scosso L, Tirost L, Malter A, Golmar JD: A new algorithm for haplotype-based association analysis: the Stochastic-EM algorithm. Ann Hum Genet 2004, 68(2 Pt 2):165-177.

28. Ilinskas M, Dahlman-Wright K, Karelmo C, Ebeling M, Gustafsson JA, Steffenen KR: Elki and SRF transcription factors convey basal transcription and mediate glucose response via their binding sites in the human LXRbeta gene promoter. Nucleic Acids Res 2007, 35(14):4858-4868.

29. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, Roix JJ, Kathiresan S, Hirschhorn JN, Daly MJ, et al.: Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007, 316(5829):1331-1336.

30. Steffenen KR, Gustafsson JA: Putative metabolic effects of the liver X receptor (LXR). Diabetes 2004, 53(Suppl 1):S36-42.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2350/10/27/prepub

Publish with BioMed Central and every scientist can read your work free of charge
"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK

Your research papers will be:
• available free of charge to the entire biomedical community
• peer reviewed and published immediately upon acceptance
• cited in PubMed and archived on PubMed Central
• yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp